Success More Than 50 Percent for Second Child With Fertility Treatment
FRIDAY, May 29, 2020 -- Women have a good chance of having a second child with the help of assisted reproductive technology (ART), according to a study published online May 8 in Human Reproduction.
Repon C. Paul, from the University of New South Wales in Sydney, and colleagues evaluated success rates for women returning to ART treatment for a second ART-conceived child. Analysis included 35,290 women who began autologous ART treatment and achieved their first treatment-dependent live birth from treatment performed from January 2009 through December 2013, with follow-up through 2015.
The researchers found that among the women who had their first ART-conceived live birth, 43 percent returned to treatment. Compared to women who underwent a new ovarian stimulation cycle, live birth rates (LBRs) were consistently better in women who recommenced treatment with a previously frozen embryo. The cumulative LBR after six cycles was between 60.9 percent (conservative) and 88.1 percent (optimal) for women who recommenced treatment with a frozen embryo versus between 50.5 and 69.8 percent for those who underwent a new ovarian stimulation cycle. For women ≥35 years, who waited at least three years before returning to treatment, or who required either a higher number of ovarian stimulation cycles or double embryo transfer to achieve their first child, the adjusted odds of a second ART-conceived live birth decreased.
"These age-specific success rates can facilitate individualized counseling for the large number of patients hoping to have a second child using ART treatment," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: May 2020
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.